Clinically actionable genetic findings by exome sequencing performed for therapeutic purposes in children with very-high risk cancer included the MAPPYACTS study
European Journal of Cancer · 2026-11 · 248 · 117449
DOI: 10.1016/j.ejca.2026.117449 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Tiphaine Adamde Beaumais und 48 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France; Université Paris-Saclay, Inserm U1018, Gustave Roussy, Villejuif,…. Hauptthemen laut MEDLINE: Genetic Predisposition to Disease, Exome Sequencing, Germ-Line Mutation, Neoplasms. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Institut National Du Cancer, Fondation ARC pour la Recherche sur le Cancer, Fédération Enfants Cancers Santé.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
INTRODUCTION: Next-generation sequencing performed for therapeutic decision-making in pediatric cancers provides an opportunity to identify germline variants associated with hereditary cancer predisposition and other actionable inherited conditions. METHODS: Germline whole-exome sequencing (WES) was performed within the MAPPYACTS (MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification) trial. Germline data were available for 674 patients with diverse relapsed or refractory malignancies. Families provided informed consent regarding disclosure of actionable germline findings. A multidisciplinary committee established a panel of 184 cancer predisposition genes with established surveillance recommendations and 49 medically actionable noncancer genes from the ACMG SF v3.1 list. Variants were analyzed using bioinformatic pipelines including quality filtering, ClinVar annotation, and computational pathogenicity assessment. RESULTS: Overall, 98.6% of families consented to the disclosure of actionable genetic findings. Among 674 patients, a total of 148 likely pathogenic or pathogenic variants (LPV/PV) were identified in 130 patients (19.3%) across 53 cancer predisposition genes. Based on inheritance patterns and clinical relevance, genetic counseling was recommended for 58 patients (8.6%). The most frequently altered genes with clinical application were TP53 (n = 17), DICER1 (n = 5), and BRCA1 (n = 4). Predisposition findings corresponded to the expected tumor spectrum in 48% of cases with 35% of them had not been previously recognized. Additionally, 10 patients (1.5%) carried actionable LPV/PV in noncancer genes associated with cardiomyopathies, familial hypercholesterolemia, or transthyretin amyloidosis. DISCUSSION: Systematic germline WES integrated into theranostic profiling may provide additional clinical value through the identification of actionable cancer predispositions and other inherited conditions. We propose recommendations for a structured, multidisciplinary framework to support clinical decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France; Université Paris-Saclay, Inserm U1018, Gustave Roussy, Villejuif, France. Electronic address: tiphaine.adam-de-beaumais@gustaveroussy.f…
- Department of Medical Biology and Pathology, Cancer Genetics Laboratory, Gustave Roussy, Villejuif, France.
- Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France; Université Paris-Saclay, Inserm U1360, Gustave Roussy, Villejuif, France.
- Department of Biochemistry and Molecular Biology, Hospices Civils de Lyon, Bron, France.
- Department of Genetics, Robert-Debré Hospital, Paris, France.
- Univ Rouen Normandie, Inserm U1245, Normandie Univ, CHU Rouen, Department of Genetics, Rouen, 76000, France.
Förderung
- Institut National Du Cancer
- Fondation ARC pour la Recherche sur le Cancer
- Fédération Enfants Cancers Santé
- Fundación Fero
- Dell Technologies
- Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'Adolescent
Zitieren
APA
Adamde Beaumais, T., Adnani, Y., Guerrini-Rousseau, L., Abbou, S., Acquaviva-Bourdain, C., Berlanga, P., Bonnard, A., Bougeard, G., Bourdeaut, F., Burnichon, N., Caputo, S., Carrié, A., Caron, O., Cavé, H., Chansavang, A., Corradini, N., Cotteret, S., Denizeau, P., Fievet, A., …, & Cabaret, O. (2026). Clinically actionable genetic findings by exome sequencing performed for therapeutic purposes in children with very-high risk cancer included the MAPPYACTS study. European Journal of Cancer, 248, 117449. https://doi.org/10.1016/j.ejca.2026.117449
Vancouver
Adamde Beaumais T, Adnani Y, Guerrini-Rousseau L, Abbou S, Acquaviva-Bourdain C, Berlanga P, et al. Clinically actionable genetic findings by exome sequencing performed for therapeutic purposes in children with very-high risk cancer included the MAPPYACTS study. European Journal of Cancer. 2026;248:117449. doi:10.1016/j.ejca.2026.117449
BibTeX
@article{AdamdeBeaumais2026,
author = {Adamde Beaumais, Tiphaine and Adnani, Yahia and Guerrini-Rousseau, Léa and Abbou, Samuel and Acquaviva-Bourdain, Cécile and Berlanga, Pablo and Bonnard, Adeline and Bougeard, Gaelle and Bourdeaut, Franck and Burnichon, Nelly and Caputo, Sandrine and Carrié, Alain and Caron, Olivier and Cavé, Hélène and Chansavang, Albain and Corradini, Nadège and Cotteret, Sophie and Denizeau, Philippe and Fievet, Alice and Filser, Mathilde and Frébourg, Thierry and Gauthier-Villars, Marion and Geoerger, Birgit and Hamzaoui, Nadim and Kasper, Edwige and Kyndt, Florence and Lacroix, Ludovic and Le Gall, Jessica and Masliah-Planchon, Julien and Pacot, Laurence and Pagan, Cécile and Pages, Mélanie and Parfait, Béatrice and Pasmant, Eric and Pierron, Gaelle and Richard, Pascale and Roux-Buisson, Nathalie and Saint-Martin, Cécile and Sassi, Hela and Schleiermacher, Gudrun and Touraine, Renaud and Uhrhammer, Nancy and Vidaud, Dominique and Brugières, Laurence and Vassal, Gilles and Rouleau, Etienne and Vial, Yoann and Golmard, Lisa and Cabaret, Odile},
title = {Clinically actionable genetic findings by exome sequencing performed for therapeutic purposes in children with very-high risk cancer included the MAPPYACTS study},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117449},
doi = {10.1016/j.ejca.2026.117449}
}
EUVIMED